Last 3,366 INR
Change Today +0.55 / 0.02%
Volume 11.4K
SANL On Other Exchanges
Symbol
Exchange
Natl India
As of 5:01 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi india ltd (SANL) Snapshot

Open
3,370
Previous Close
3,365
Day High
3,475
Day Low
3,345
52 Week High
11/21/14 - 3,800
52 Week Low
02/17/14 - 2,500
Market Cap
77.5B
Average Volume 10 Days
18.2K
EPS TTM
63.00
Shares Outstanding
23.0M
EX-Date
07/31/14
P/E TM
53.4x
Dividend
45.00
Dividend Yield
1.34%
Current Stock Chart for SANOFI INDIA LTD (SANL)

Related News

No related news articles were found.

sanofi india ltd (SANL) Related Businessweek News

No Related Businessweek News Found

sanofi india ltd (SANL) Details

Sanofi India Limited manufactures and sells pharmaceutical products in India and internationally. It provides medicines for the treatment of patients in various therapeutic areas, such as cardiology, thrombosis, oncology, diabetes, central nervous system, internal medicine, and consumer healthcare. The company also offers medicines for the treatment of respiratory systems, dermatology, analgesics, anti-infectives, bone and joint diseases, and gastrointestinal disorders. It primarily provides its products under the brand names of Cardace, Lantus, Insuman, Apidra, All Star, Amaryl, Cetapin, Clexane, Targocid, Allegra, Taxotere, Combiflam Plus, Novalgin NU, Baralgin NU, Seacod, Avil, and Enlarge Forte. The company was incorporated in 1956 and is based in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

3,291 Employees
Last Reported Date: 03/31/14
Founded in 1956

sanofi india ltd (SANL) Top Compensated Officers

Managing Director, Vice President of South As...
Total Annual Compensation: 8.6M
Chief Financial Officer, Chief Financial Offi...
Total Annual Compensation: 6.1M
Commercial Operations Officer
Total Annual Compensation: 1.3M
Compensation as of Fiscal Year 2013.

sanofi india ltd (SANL) Key Developments

Sanofi India Limited Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Sanofi India Limited announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total income from operations (net) of INR 5,149 million against INR 4,974 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 799 million against INR 1,012 million a year ago. Profit before tax and exceptional items was INR 940 million against INR 1,165 million a year ago. Net profit after exceptional items of INR 620 million or INR 26.93 per basic and diluted share against INR 769 million or INR 33.43 per basic and diluted share a year ago. For the nine months, the company reported total income from operations (net) of INR 14,656 million against INR 13,206 million a year ago. Profit from operations before other income and finance costs was INR 2,108 million against INR 2,157 million a year ago. Profit before tax and exceptional items was INR 2,595 million against INR 2,614 million a year ago. Net profit after exceptional items was INR 1,712 million or INR 74.37 per basic and diluted share against INR 1,726 million or INR 75.04 per basic and diluted share a year ago.

Sanofi India Limited to Report Q3, 2014 Results on Nov 11, 2014

Sanofi India Limited announced that they will report Q3, 2014 results on Nov 11, 2014

Sanofi India Limited, Board Meeting, Nov 11, 2014

Sanofi India Limited, Board Meeting, Nov 11, 2014. Agenda: To consider the unaudited financial results for the quarter and nine months ended September 30, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANL:IN 3,366.00 INR +0.55

SANL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 3,380 INR -16.75
Cadila Healthcare Ltd 1,500 INR -35.10
Medivation Inc $109.17 USD +2.55
Pfizer Ltd/India 2,050 INR +49.80
Piramal Enterprises Ltd 801.00 INR +5.95
View Industry Companies
 

Industry Analysis

SANL

Industry Average

Valuation SANL Industry Range
Price/Earnings 32.3x
Price/Sales 3.9x
Price/Book 5.4x
Price/Cash Flow 21.4x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI INDIA LTD, please visit www.aventispharmaindia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.